Segui
Sergio Valente
Sergio Valente
Associate Professor, Sapienza University Rome
Email verificata su uniroma1.it
Titolo
Citata da
Citata da
Anno
Mapping the human genetic architecture of COVID-19
Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ...
Nature 600 (7889), 472-477, 2021
7252021
TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration
D Palacios, C Mozzetta, S Consalvi, G Caretti, V Saccone, V Proserpio, ...
Cell stem cell 7 (4), 455-469, 2010
4392010
Histone deacetylation in epigenetics: an attractive target for anticancer therapy
A Mai, S Massa, D Rotili, I Cerbara, S Valente, R Pezzi, S Simeoni, ...
Medicinal research reviews 25 (3), 261-309, 2005
4192005
Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2
C Binda, S Valente, M Romanenghi, S Pilotto, R Cirilli, A Karytinos, ...
Journal of the American Chemical Society 132 (19), 6827-6833, 2010
3442010
Oxidative stress and epigenetic regulation in ageing and age-related diseases
C Cencioni, F Spallotta, F Martelli, S Valente, A Mai, AM Zeiher, ...
International journal of molecular sciences 14 (9), 17643-17663, 2013
2692013
Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue
A Galmozzi, N Mitro, A Ferrari, E Gers, F Gilardi, C Godio, G Cermenati, ...
diabetes 62 (3), 732-742, 2013
2472013
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
JH Kalin, M Wu, AV Gomez, Y Song, J Das, D Hayward, N Adejola, M Wu, ...
Nature communications 9 (1), 53, 2018
1992018
Study of 1, 4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors
A Mai, S Valente, S Meade, V Carafa, M Tardugno, A Nebbioso, ...
Journal of medicinal chemistry 52 (17), 5496-5504, 2009
1792009
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes
A Nebbioso, F Manzo, M Miceli, M Conte, L Manente, A Baldi, A De Luca, ...
EMBO reports 10 (7), 776-782, 2009
1742009
Epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors
A Mai, D Cheng, MT Bedford, S Valente, A Nebbioso, A Perrone, ...
Journal of medicinal chemistry 51 (7), 2279-2290, 2008
1622008
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
R Mazzone, C Zwergel, A Mai, S Valente
Clinical epigenetics 9 (1), 59, 2017
1432017
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities
D Rotili, S Tomassi, M Conte, R Benedetti, M Tortorici, G Ciossani, ...
Journal of medicinal chemistry 57 (1), 42-55, 2014
1342014
Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling
B Illi, CD Russo, C Colussi, J Rosati, M Pallaoro, F Spallotta, D Rotili, ...
Circulation research 102 (1), 51-58, 2008
1332008
1, 3, 4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells
S Valente, D Trisciuoglio, T De Luca, A Nebbioso, D Labella, A Lenoci, ...
Journal of medicinal chemistry 57 (14), 6259-6265, 2014
1322014
Specific activity of class II histone deacetylases in human breast cancer cells
V Duong, C Bret, L Altucci, A Mai, C Duraffourd, J Loubersac, ...
Molecular Cancer Research 6 (12), 1908-1919, 2008
1312008
" Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models …
A Savarino, A Mai, S Norelli, S El Daker, S Valente, D Rotili, L Altucci, ...
Retrovirology 6, 1-10, 2009
1292009
Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells
S Valente, Y Liu, M Schnekenburger, C Zwergel, S Cosconati, C Gros, ...
Journal of medicinal chemistry 57 (3), 701-713, 2014
1252014
Six years (2012–2018) of researches on catalytic ezh2 inhibitors: the boom of the 2‐pyridone compounds
R Fioravanti, G Stazi, C Zwergel, S Valente, A Mai
The Chemical Record 18 (12), 1818-1832, 2018
982018
Aurones: interesting natural and synthetic compounds with emerging biological potential
C Zwergel, F Gaascht, S Valente, M Diederich, D Bagrel, G Kirsch
Natural product communications 7 (3), 1934578X1200700322, 2012
972012
A nitric oxide-dependent cross-talk between class I and III histone deacetylases accelerates skin repair
F Spallotta, C Cencioni, S Straino, S Nanni, J Rosati, S Artuso, I Manni, ...
Journal of Biological Chemistry 288 (16), 11004-11012, 2013
962013
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20